THX Pharma and Biocodex Sign Licensing Agreement for Three Rare Diseases
THX Pharma and Biocodex have announced the signing of a strategic licensing agreement for two drug candidates aimed at treating three rare neurological diseases: Batten disease, Gaucher disease, and Niemann-Pick disease type C.
Details of the Licensing Agreement
The agreement involves Biocodex acquiring two licenses from THX Pharma. The first license covers the global development and commercial exploitation of Batten-1, a drug candidate intended for the treatment of juvenile Batten disease (CLN3). The second license pertains to the development and commercial exploitation in the United States and Canada of TX01, a new formulation of an already approved molecule intended for the treatment of Gaucher disease and Niemann-Pick disease type C. The three targeted diseases are genetic disorders often pediatric, leading to severe and progressive visceral, hematological, or neurological damage.
Financial Terms and Development Milestones
THX Pharma will receive a total amount that could reach €173 million, including an initial payment of €12 million and up to €161 million in development and commercialization milestone payments, as well as double-digit royalties on net sales. THX Pharma will lead the clinical development of the programs with financial and scientific support from Biocodex. Biocodex will handle compassionate access, market access, and commercialization activities in the territories covered by the licenses. For Batten-1, an international launch is anticipated by 2030, with phase 3 commencement planned for 2026.
Biocodex's Ongoing Commitment to Rare Neurological Diseases
This agreement continues Biocodex's commitment to rare neurological diseases, based on over thirty years of expertise combining scientific rigor, long-term clinical development, and attention to patient life journeys. Biocodex is an independent French pharmaceutical laboratory present in over 100 countries. THX Pharma is a biopharmaceutical company specializing in the development of innovative treatments for rare neurological diseases.
